![Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - - Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - -](https://onlinelibrary.wiley.com/cms/asset/84188f30-c534-4f49-a5a8-6769a35bc872/ene15171-fig-0002-m.jpg)
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - -
![Odds of achieving a NEDA-3 status at age 20 years, age 30 years and in... | Download Scientific Diagram Odds of achieving a NEDA-3 status at age 20 years, age 30 years and in... | Download Scientific Diagram](https://www.researchgate.net/publication/325374549/figure/fig2/AS:630344415997952@1527297228210/Odds-of-achieving-a-NEDA-3-status-at-age-20-years-age-30-years-and-in-the-overall_Q640.jpg)
Odds of achieving a NEDA-3 status at age 20 years, age 30 years and in... | Download Scientific Diagram
![NEDA Früchtewürfel Würfel 15 Stück | Human Arzneimittel | Human Arzneimittel | Arzneimittel | ReboPharm | Online-Shop NEDA Früchtewürfel Würfel 15 Stück | Human Arzneimittel | Human Arzneimittel | Arzneimittel | ReboPharm | Online-Shop](https://rebopharm24.imgbolt.de/media/image/6f/39/3a/Med-Pharma-Service.jpg)